Analytical Data
-
Gene name
TAL1
- Application
-
Alternative Names
TAL1；BHLHA17；SCL；TCL5；T-cell acute lymphocytic leukemia Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P17542
-
Expression Region
1-331aa
-
AA Sequence
MTERPPSEAA RSDPQLEGRD AAEASMAPPH LVLLNGVAKE TSRAAAAEPP VIELGARGGP GGGPAGGGGA ARDLKGRDAA TAEARHRVPT TELCRPPGPA PAPAPASVTA ELPGDGRMVQ LSPPALAAPA APGRALLYSL SQPLASLGSG FFGEPDAFPM FTTNNRVKRR PSPYEMEITD GPHTKVVRRI FTNSRERWRQ QNVNGAFAEL RKLIPTHPPD KKLSKNEILR LAMKYINFLA KLLNDQEEEG TQRAKTGKDP VVGAGGGGGG GGGGAPPDDL LQDVLSPNSS CGSSLDGAAS PDSYTEEPAP KHTARSLHPA MLPAADGAGP R
-
Molecular Weight
34.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TAL1, also known as T-cell acute lymphocytic leukemia 1, is a transcription factor that plays a crucial role in hematopoiesis and the development of various blood cells. Its dysregulation is implicated in hematological malignancies, particularly in T-cell acute lymphoblastic leukemia (T-ALL). The study of TAL1 recombinant proteins is essential for understanding its functional mechanisms and the pathways it influences in normal and pathological conditions. By expressing TAL1 as a recombinant protein, researchers can investigate its interactions with other proteins, DNA elements, and the overall impact on gene expression regulation. This research not only enhances our understanding of TAL1's role in leukemogenesis but also aids in the identification of potential therapeutic targets for T-ALL and other related disorders. Furthermore, recombinant TAL1 can serve as a valuable tool for drug screening and the development of innovative treatments, as it allows for the evaluation of compound effects on TAL1 activity in controlled experimental settings. Overall, the study of TAL1 and its recombinant forms is a pivotal aspect of cancer research, providing insights into fundamental biological processes and paving the way for novel therapeutic strategies.
